Angela DeMichele, MD, MSCE, leads study on breast cancer drug Raloxifene, also shown to reduce risk of endometrial cancer

September 30, 2008


Tamoxifen and raloxifene drugs revolutionized breast cancer care about10 years ago, helping to reduce the risk of breast cancer for many women world-wide. During this time Penn has played an active part in researching how effective these drugs are and discovering their differences. A recent study, lead by Angela DeMichele, MD, MSCE, Abramson Cancer Center oncologist and assistant professor of Medicine and Epidemiology, and published in the September issue of the Journal of Clinical Oncology, was featured in Reuter’s, HealthDay,  and Dr. DeMichele and colleagues found that while raloxifene and tamoxifen are similarly effective in reducing breast cancer risk, raloxifene also appears to offer the added benefit of reducing the risk of endometrial cancer. These results are important, says Dr. DeMichele, “because they suggest a critical difference between tamoxifen and raloxifene that could help physicians in tailoring therapy to the patient.

View Full Article
View MSN Article